Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: New Constructs, LLC
Provider: ValuEngine, Inc.
Provider: Pechala's Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

BioScrip Inc Reaffirms FY 2013 Guidance

Wednesday, 8 May 2013 05:30pm EDT 

BioScrip Inc announced that it reaffirms its initial 2013 revenue target of $830.0 million to $865.0 million and 2013 Adjusted EBITDA target of $67.0 million to $73.0 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $837.7 million for fiscal 2013. 

Company Quote

-0.12 -1.46%
4:00pm EDT